Rituximab (B cell) + steroid vs steroids: Failure of acute rejection reversal
Rituximab (B cell) + steroid showed no clear difference in failure of reversal of acute rejection compared with steroid alone (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Rituximab (B cell) + steroid vs steroid alone Failure of reversal of acute rejection · kidney transplant recipients: first rejection episode Rituximab (B cell) + steroid showed no clear difference in failure of reversal of acute rejection compared with steroid alone (moderate certainty). Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients (2017) · Cochrane Headline outcomes only | RR 0.94 [0.54, 1.64] | 2 studies · 53 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Polyclonal and monoclonal antibodies for treating acute rejection episodes in kidney transplant recipients 2017 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.